KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Deffered Revenue (2021 - 2024)

Travere Therapeutics (TVTX) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $888000.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Non-Current Deffered Revenue fell 89.88% year-over-year to $888000.0, compared with a TTM value of $888000.0 through Mar 2024, down 89.88%, and an annual FY2023 reading of $1.8 million, down 83.21% over the prior year.
  • Non-Current Deffered Revenue was $888000.0 for Q1 2024 at Travere Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $24.1 million in Q3 2021 and bottomed at $888000.0 in Q1 2024.
  • Average Non-Current Deffered Revenue over 4 years is $11.6 million, with a median of $10.9 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue plummeted 46.36% in 2022, then plummeted 89.88% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $20.4 million in 2021, then plummeted by 46.36% to $10.9 million in 2022, then tumbled by 83.21% to $1.8 million in 2023, then crashed by 51.61% to $888000.0 in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for TVTX at $888000.0 in Q1 2024, $1.8 million in Q4 2023, and $4.6 million in Q3 2023.